Note: This document has been translated from a part of the Japanese original, and is for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

Stock Exchange Code 4202 June 3, 2021

To Shareholders with Voting Rights:

Misao Fudaba Chairman of Board of Directors Daicel Corporation 3-1, Ofuka-cho, Kita-ku, Osaka, Japan

NOTICE OF

THE 155TH ANNUAL GENERAL MEETING OF SHAREHOLDERS

Dear Shareholders:

We would like to express our appreciation for your continued support and patronage.

You are hereby notified that the 155th Annual General Meeting of Shareholders of Daicel Corporation (the "Company") will be held for the purposes described below.

From the perspective of preventing the spread of COVID-19 and ensuring the safety and security of our shareholders, we would like to ask all our shareholders to exercise your voting rights in advance in writing or via the Internet, etc. as much as possible instead of attending the General Meeting of Shareholders.

Please review the hereinafter attached "Reference Documents for the General Meeting of Shareholders" and exercise your voting rights in writing or via the Internet, etc. by 5:00 p.m. on Thursday, June 24, 2021, Japan time.

1. Date and Time:	Friday, June 25, 2021 at 10:00 a.m. Japan time (Reception begins at 9:00 a.m.)
2. Place:	Knowledge Theater, 4F, North Wing of GRAND FRONT OSAKA located at 3- 1 Ofuka-cho, Kita-ku, Osaka, Japan
3. Meeting Agenda:	
Matters to be reported:	 The Business Report, Consolidated Financial Statements for the Company's 155th Fiscal Year (April 1, 2020 - March 31, 2021) and results of audits by the Accounting Auditor and the Audit & Supervisory Board of the Consolidated Financial Statements Non consolidated Financial Statements
	2. Non-consolidated Financial Statements for the Company's 155th Fiscal Year (April 1, 2020 - March 31, 2021)
Proposals to be resolved	1:
Proposal 1:	Appropriation of Surplus
Proposal 2:	Election of 10 Directors

- When attending the meeting, please submit the enclosed Voting Rights Exercise Form at the reception desk. Please bring this convocation notice to the meeting with you to help save resources.
- Should the Reference Documents for the General Meeting of Shareholders and the Appendix require revisions, the revised versions will be posted on the Company's website (https://www.daicel.com).
- Of the documents to be provided with this notice, "Consolidated Statement of Changes in Equity" and "Notes to the Consolidated Financial Statements" of the Consolidated Financial Statements and "Non-consolidated Statement of Changes in Equity" and "Notes to the Non-consolidated Financial Statements" of the non-Consolidated Financial Statements are posted on the Company's website (https://www.daicel.com) on the Internet, pursuant to applicable laws and regulations, as well as the provisions in Article 16 of the Articles of the Incorporation. Therefore, they are not stated in the Appendix concerning the matters to be reported. "Consolidated Financial Statements and "Non-consolidated Financial Statements" of the Consolidated Financial Statements of the Non-consolidated Financial Statements of the non-Consolidated Financial Statements" of the Consolidated Financial Statements of the Non-consolidated Financial Statements of the non-consolidated Financial Statements of the Consolidated Financial Statements of the Non-consolidated Financial Statements of the non-consolidated Financial Statements as well as the Appendix concerning the matters to be reported are subject to audit by the Accounting Auditor and the Audit & Supervisory Board Members.
- To help conserve electricity, the air conditioning at the venue will be partially turned down. We would appreciate it if you could come to the meeting wearing light clothing.
- Please note that our officers and staff will be in light clothing ("cool biz") at the meeting.

<Notes to shareholders>

- We may update the above measures upon the situation of the spread of the disease and announcements made by the government until the day of the General Meeting of Shareholders. Please check the Company's website (https://www.daicel.com) on the Internet for the transmission of information.
- Attending shareholders are requested to bring and wear a face mask. We will set alcohol hand sanitizer for you to use near the reception desk at the meeting.
- We will take your temperature near the venue. Shareholders with fever and those that seem to be in a poor health condition may be asked not to enter the venue.
- Our officers and operation staff of the General Meeting of Shareholders will take their temperatures and confirm their health conditions, and wear a face mask.
- The number of seats available at the venue will be limited in order to prevent the spread of COVID-19. Please note that we may ask our shareholders not to enter the venue if the number of attendees exceeds the maximum number of seats available. From the viewpoint of shortening the meeting, we are considering ways to make the process proceed more smoothly than in previous years. We ask that you please read through the Notice in advance.

Reference Documents for the General Meeting of Shareholders

Proposals and References

Proposal 1: Appropriation of Surplus

Concerning the appropriation of surplus, the Company proposes as follows:

Matters concerning the year-end dividends

The Company's basic dividend policy is to distribute profits in a balanced manner, taking into comprehensive consideration maximizing asset efficiency and realizing optimal capital structure, ensuring financial soundness in order to maintain fund raising capacity, and stable consolidated business performance.

Internal reserves will be applied to investment in business expansion and reinforcement of highlyprofitable business structures, such as R&D for new business development and strengthening of existing businesses, new construction and extension of facilities, and efficiency improvement measures. Through future business development, we will ensure a growing benefit to our shareholders.

In the Company's mid-term management strategy, "Accelerate 2025," which started in FY2020, we have targeted a shareholder return ratio of 40% or more for each fiscal year, combining the amount of dividends with the amount of flexible acquisition of the Company's own stocks, with the current dividend per share as the lower limit.

Based on the policy mentioned above, the year-end dividend for the fiscal year under review will be 16 yen per share.

- (1) Type of dividend property Cash
- (2) Matters concerning the allotment of dividend property to shareholders and the total amount thereof
 16 yen per share of common stock of the Company
 Total amount: 4,821,328,784 yen
 (Note) The annual dividends for the fiscal year under review will be 32 yen per share including the interim dividends.
- (3) Effective date of distribution of surplus June 28, 2021

Proposal 2: Election of 10 Directors

The terms of office of all 10 Directors will expire at the conclusion of this year's Annual General Meeting of Shareholders. Accordingly, the election of 10 Directors is proposed. The candidates for Directors are as follows:

No.	Name	Current Positions and Responsibilities at the Con	npany
1	Misao Fudaba	Chairman of Board of Directors, Member of the Nomination and Compensation Committee	Reappointment
2	Yoshimi Ogawa	President and CEO, President, Member of the Nomination and Compensation Committee, Chairman of the Management Advisory Committee, Responsible for Research Center and Executive Consultant of Polyplastics Co., Ltd.	Reappointment
3	Kotaro Sugimoto	Representative Director, Senior Managing Executive Officer, Member of the Nomination and Compensation Committee, Member of the Management Advisory Committee, General Manager of Corporate Support Headquarters, Responsible for Corporate Compliance Program and Responsible for Corporate Sustainability	Reappointment
4	Yasuhiro Sakaki	Director, Senior Managing Executive Officer, Member of the Management Advisory Committee, General Manager of Corporate Planning & Strategy Headquarters, Responsible for Safety SBU, Responsible for Healthcare SBU and Responsible for Raw Material Purchasing Center	Reappointment
5	Akihisa Takabe	Director, Managing Executive Officer, Member of the Management Advisory Committee, General Manager of Innovation and Business Development Headquarters, Responsible for Intellectual Property Center and Responsible for CPI Company	Reappointment
6	Masafumi Nogimori	Director and Chairman of the Nomination and Compensation Committee	Reappointment Outside Independent
7	Teisuke Kitayama	Director and Member of the Nomination and Compensation Committee	Reappointment Outside Independent
8	Sonoko Hacchoji	Director and Member of the Nomination and Compensation Committee	Reappointment Outside Independent
9	Toshio Asano	Director and Member of the Nomination and Compensation Committee	Reappointment Outside Independent
10	Takeshi Furuichi	Director and Member of the Nomination and Compensation Committee	Reappointment Outside Independent

No.	Name (Date of birth)	Past experience, positions, responsil and significant concurrent pos		Number of shares of the Company held
1	Misao Fudaba (February 23, 1956) Reappointment	April 1979Joined the CompanyJune 2006Executive Officer of the Company Deputy Head of Corporate Support O June 2008June 2008Head of Raw Material Purchasing CJune 2010President of the Company President and CEO of the Company Of the Company Deputy Chairman of Board of Directors of the (Positions and responsibilities) Chairman of Board of Directors and and Compensation Committee[Reasons for selection as a candidate for Director] Mr. Misao Fudaba has served as President and CEO of 2019, and since he assumed his role as Chairman of achievements in contributing to the improvement of corp Based on his wealth of experience, achievements and ins of the Company's group management and global thus requests his election as Director.	enter of the Company he Company Member of the Nomination the Company from 2010 to Board of Directors, he has worate value as the Chairman. tights in overall management is an appropriate person to	140,120

No.	Name (Date of birth)	Past experience, positions, responsibilities and significant concurrent positions	Number of shares of the Company held
2	Yoshimi Ogawa (January 8, 1960) Reappointment	April 1983Joined the CompanyJune 2000Head of Production Innovation Center, Production Technology Headquarters of the CompanyApril 2002Head of Business Process Innovation of the Company June 2006June 2006Executive Officer of the Company Vice President of Aerospace & Defense Systems/Safety Systems Company of the Company General Manager of Harima Plant, Aerospace & Defense Systems/Safety Systems Company of the Company Responsible for Responsible Care of the Company Responsible for Responsible Care of the Company Responsible for Engineering Center of the Company April 2011June 2011Director of the Company Responsible for Production Technology of the Company April 2014April 2015Responsible for Quality Management Division of the Company April 2015April 2016Responsible for Quality Management Division of the Company Responsible for Aerospace & Defense Systems/Safety Systems Company Company of the CompanyJune 2017Senior Managing Executive Officer of the Company President of the CompanyJune 2019President of the Company Responsible for Research Center of the Company 	97,646

No.	Name (Date of birth)		Past experience, positions, responsibilities and significant concurrent positions	Number of shares of the Company held
3	Kotaro Sugimoto (October 10, 1960) Reappointment	Mr. Kotaro Sugi divisions including person for the Raw experience, achiev Company has dete	Joined the Company Head of Raw Material Purchasing Center of the Company Executive Officer of the Company Representative Director and President of Daicel Logistics Service Co., Ltd. Managing Executive Officer of the Company Responsible for Business Process Innovation of the Company Representative Director of the Company General Manager of Corporate Support Center of the Company Responsible for Corporate Compliance Program of the Company Responsible for Corporate Sustainability of the Company General Manager of Corporate Support Headquarters of the Company Senior Managing Executive Officer of the Company Responsible for Corporate Sustainability of the Company General Manager of Corporate Support Headquarters of the Company Senior Managing Executive Officer of the Company (Positions and responsibilities) Representative Director, Senior Managing Executive Officer, Member of the Nomination and Compensation Committee, Member of the Management Advisory Committee, General Manager of Corporate Support Headquarters, Responsible for Corporate Compliance Program and Responsible for Corporate Sustainability tion as a candidate for Director] moto has served as the responsible person for administrative ginance and accounting and compliance, as well as the responsible v Material Purchasing Center of the Company, and has a wealth of vements and insights in the management of the Company. The rmined that he is an appropriate person to promote the Company's at and global business management, and thus requests his election	42,455

No.	Name (Data of high)		Past experience, positions, responsibilities	Number of shares of the
	(Date of birth)		and significant concurrent positions	Company held
		April 1984 June 2012 June 2014 June 2016	Joined the Company President of Organic Chemical Products Company of the Company Executive Officer of the Company President of Aerospace & Defense Systems/Safety Systems Company of the Company	
		June 2017	 President of Daicel Safety Systems (Jiangsu) Co., Ltd. Managing Executive Officer of the Company President & CEO of Daicel Safety Systems America Holdings, Inc. President & CEO of Daicel Safety Systems America Arizona, Inc. President & CEO of Special Devices, Inc. 	
		April 2019 June 2019	Chairman of Daicel Safety Systems Americas, Inc. Senior Managing Executive Officer of the Company Responsible for Aerospace & Defense Systems/Safety Systems Company of the Company	
		October 2019	General Manager of Strategic Planning Headquarters of the Company	
4	Yasuhiro Sakaki (March 17, 1962)	April 2020	Responsible for Safety SBU of the Company Responsible for Healthcare SBU of the Company	10 5 17
4	Reappointment	June 2020	Director of the Company Responsible for Raw Material Purchasing Center of the Company	40,547
		April 2021	General Manager of Corporate Planning & Strategy Headquarters of the Company	
			(Positions and responsibilities) Director, Senior Managing Executive Officer, Member of the Management Advisory Committee, General Manager of Corporate Planning & Strategy Headquarters, Responsible for Safety SBU, Responsible for Healthcare SBU and Responsible for Raw Material Purchasing Center	
		[Reasons for sele	ection as a candidate for Director]	1
			kaki has served as the responsible person for pyrotechnic devices of	
		· ·	resident of overseas subsidiaries, as well as the responsible person	
			olving strategic planning of the Company, and has a wealth of evements and insights in the management of the Company. The	
		▲ ·	termined that he is an appropriate person to promote the Company's The	
			ent and global business management, and thus requests his election	

No.	Name (Date of birth)		Past experience, positions, responsibilities and significant concurrent positions	Number of shares of the Company held
5	Akihisa Takabe (January 20, 1960) Reappointment	Mr. Akihisa Tal fundamental tech including produc development, and product planning he is an appropria	Joined the Company Representative Director and President of Daicel Safety Systems Inc. Head of Central Research Center of the Company Head of Corporate Research Center of R&D Headquarters of the Company Deputy General Manager of R&D Headquarters of the Company Executive Officer of the Company Director of the Company General Manager of R&D Headquarters of the Company Responsible for New Business Development of the Company Responsible for Intellectual Property Center of the Company Responsible for Quality Management Division of the Company General Manager of Innovation and Business Development Headquarters of the Company Managing Executive Officer of the Company Responsible for CPI Company of the Company Responsible for CPI Company of the Company Cignificant concurrent positions) Director, Managing Executive Officer, Member of the Management Advisory Committee, General Manager of Innovation and Business Development Headquarters, Responsible for Intellectual Property Center and Responsible for CPI Company ction as a candidate for Director] kabe has served as the responsible person for the Company's nologies and research and development divisions in various areas t development, as well as divisions involved in new business has a wealth of experience, achievements and insights in the new and development of the Group. The Company has determined that te person to promote the Company's group management and global nent, and thus requests his election as Director.	29,799

No.	Name	Past experience, positions, responsibilities		Number of shares of the
INO.	(Date of birth)	and significant concurrent positions		Company held
6	Masafumi Nogimori (December 21, 1947) Reappointment Outside Independent	 April 2005 Executive Vice President and Representative Astellas Pharma Inc. June 2006 President & CEO and Representative Direct Pharma Inc. June 2011 Chairman and Representative Director of As June 2016 Retired from Chairman and Representative I Pharma Inc. June 2017 Director of the Company (Positions and responsibilities) Director and Chairman of the Nomination an Committee (Significant concurrent positions) Outside Director of Mitsui Fudosan Co., Ltd. [Reasons for selection as a candidate for Outside Director and experience manager of a company that produces and sells medical produc utilize his point of view based on these insights and experience management of the Company, the Company requests his election The Company expects Mr. Masafumi Nogimori to fulfill the abafter his reappointment. [Matters specifically noted regarding the candidate for Outside Directors held during the 155th Fiscal Year. Mr. Masafumi Nogimori has taken on roles such as Represe President at Astellas Pharma Inc., a business partner of the retired from the position of Representative Director and CPharma Inc. in June 2016, he has not been involved in its The Group has no business transactions with Astellas groyear. The Company has registered him as an independent director Exchange, pursuant to the rules stipulated by the Exchang approved, the Company plans to continue registering furctor. Additionally, he satisfies the "Standards for Independence of Outside Audit & Supervisory Board Members" defined by to the text of the Standards for Independence of Outside Audit & Supervisory Board Members" defined by to the furctor of Astendards for Independence of Outside Audit & Supervisory Board Members" defined by to the furctor of the rules the head of the rules the head of the director functors / Outside Audit & Supervisory Board Members" defined by to th	e Director of for of Astellas stellas Pharma Inc. Director of Astellas and Compensation expected roles] re, etc., fostered as a cts, and to have him erience, etc. in the as Outside Director. ove-mentioned roles Director] ector for a period of shareholders. ' meetings that were entative Director and Company. Since he chairman of Astellas business execution. up during the fiscal or with Tokyo Stock ge. If his election is him as independent pendence of Outside '' as defined by the Outside Directors / the Company, please	2,276
		refer to the standard which is attached on the last portion Documents.		

No.	Name (Date of birth)		Past experience, positions, responsibilities and significant concurrent positions	Number of shares of the Company held
No.		Mr. Teisuke Kita manager of finan- these insights and requests his elec Kitayama to fulfil [Matters specifica • Mr. Teisuke	and significant concurrent positions Director President (Representative Director) of Sumitomo Mitsui Financial Group, Inc. Chairman of the Board (Representative Director) of Sumitomo Mitsui Banking Corporation Retired from Director of Sumitomo Mitsui Financial Group, Inc. Chairman of the Board of Sumitomo Mitsui Banking Corporation Director of Sumitomo Mitsui Banking Corporation Advisor of Sumitomo Mitsui Banking Corporation Director of the Company Honorary Advisor of Sumitomo Mitsui Banking Corporation (Positions and responsibilities) Director and Member of the Nomination and Compensation Committee (Significant concurrent positions) Honorary Advisor of Sumitomo Mitsui Banking Corporation Outside Auditor of TBS HOLDINGS, INC. ction as a candidate for Outside Director and expected roles] yama has a wealth of insights and experience, etc., fostered as a cial institutions, and to have him utilize his point of view based on experience, etc. in the management of the Company, the Company tion as Outside Director. The Company expects Mr. Teisuke I the above-mentioned roles after his reappointment. Illy noted regarding the candidate for Outside Director for a period of three	
	Outside	 Mr. Teisuke years as of th Mr. Teisuke held during t Mr. Teisuke (Representat the Company Sumitomo M in said bank' bank is equi assets. Approthe the business Therefore, th Kitayama as The Company Exchange, p approved, th director. Add Directors / C Company. R Outside Aud 		

Name		Past experience, positions, responsibilities	Number of
(Date of birth)	th)	and significant concurrent positions	
	November 1993March 2002January 2006March 2011April 2017June 2019April 2020[Reasons for selectMs. Sonoko Haccmember of a mancompany, and toexperience, etc. irelection as Outsidethe above-mention[Matters specifical• Ms. Sonoko Fyears as of the• Ms. Sonoko Fyears as of the• Ms. Sonoko Fthat were held• Japan AirlineDirector, recetransportation("MLIT") oneffects on air sand decisions2019, said corregular basisof legal and reshe fulfilled hthese cases an• The CompanyExchange, pu		shares of the Company held

April 2010 President & Representative Director, Presidential Executive Officer of Asahi Kasei Pharma Corp. April 2014 Presidential Executive Officer of Asahi Kasei Corp.	Company held
9 Institution of the series series of the series of the series of the series of th	0

No.
10

(Notes)

- 1. Mr. Takeshi Furuichi is Representative Director and Vice Chairman of Nippon Life Insurance Company, and the Company has borrowing of funds and insurance transactions with the said company. There are no special interests between each of other candidates for Director and the Company.
- Mr. Masafumi Nogimori, Mr. Teisuke Kitayama, Ms. Sonoko Hacchoji, Mr. Toshio Asano and Mr. Takeshi Furuichi are candidates for Outside Directors.
- 3. Liability limitation agreements with the candidate for Outside Director The Company has entered into a liability limitation agreement with Mr. Masafumi Nogimori, Mr. Teisuke Kitayama, Ms. Sonoko Hacchoji, Mr. Toshio Asano and Mr. Takeshi Furuichi that the limit of his/her liability for damages stipulated in Article 423 Paragraph 1 of the Companies Act shall be ¥15 million or the minimum liability amount set forth in Article 425 Paragraph 1 of the Companies Act, whichever is higher, only in cases where they have performed their duties which caused liabilities in good faith and without gross negligence. Subject to the approval of the election of Mr. Masafumi Nogimori, Mr. Teisuke Kitayama, Ms. Sonoko Hacchoji, Mr. Toshio Asano and Mr. Takeshi Furuichi, the Company plans to continue said liability limitation agreement with them.

4. Directors and Officers Liability Insurance contract for the candidates for Directors The Company has entered into a contract of Directors and Officers Liability Insurance with an insurance company, as stipulated in Article 430-3 Paragraph 1 of the Companies Act. This insurance contract covers damages that may arise from the insured director assuming liability for the execution of his or her duties or receiving claims related to the pursuit of such liability.

However, there are certain exclusions, such as no coverage for damages arising from a criminal act of the insured or an action taken by the insured with the knowledge that it was in violation of laws and regulations.

Subject to the approval of each candidate as Director, they will be insured under said insurance contract. The Company intends to renew said insurance contract with the same details during their terms of office.

[For reference] Standards for Independence of Outside Directors/Audit & Supervisory Board Members

The independence of Outside Directors/Audit & Supervisory Board Members of the Company refers to such a person being independent from the Company's management without falling under any of the following:

- 1. A person executing the business, etc. ("Executing Person") of the Company (*1) and its affiliates (hereinafter, "the Group") and their relatives, etc.(*2);
- 2. A party for which the Group is a principal business partner (*3) or an Executing Person thereof;
- 3. A principal business partner of the Group (*4) or an Executing Person thereof;
- 4. A major shareholder of the Company (*5) or an Executing Person thereof;
- 5. A director and other Executing Person of an organization (*6) that has received a certain amount or more of donations or subsidies from the Group;
- 6. A consultant, certified public accountant or other accounting professional, or lawyer or other legal professional who has received a substantial amount of monetary compensation or other consideration other than director / audit & supervisory board member compensation from the Group (*7) (if the party receiving such consideration is a corporation, association or other entity, a person belonging to the said entity or a person who has belonged to the said entity in the past three years).
- (*1) An Executing Person refers to those who conduct business operations or conducted business operations within the past three years, including directors (excluding Outside directors), executive officers and employees.
- (*2) Relatives refer to relatives within the second degree of kinship of those who conduct important business operations, including directors (excluding Outside directors), executive officers and division managers.
- (*3) A party for which the Group is a principal business partner refers to a business partner group (which means entities that belong to the consolidated group to which the direct business partner belongs; the same shall apply hereinafter) that supplies products and services to the Group, where the business partner group's trading amount with the Group exceeds 2% of the consolidated sales of the business partner group in the any of the recent past three fiscal years.
- (*4) A principal business partner of the Group refers to those who fall under either of the following:
 - (1) A business partner group to whom the Group supplies products and services, where the Group's trading amount with such group exceeds 2% of the Group's consolidated sales in the any of the recent past three fiscal years.
 - (2) A financial institution group (which means entities that belong to the consolidated group to which the direct lender belongs) from which the Group has borrowed funds, where the total amount of the Group's borrowings from the financial institution group exceeds 2% of the Group's consolidated total assets at the end of the any of the recent past three fiscal years.
- (*5) A major shareholder of the Company refers to those who directly or indirectly hold voting interests of 10% or more.
- (*6) An organization that has received a certain amount or more of donations or subsidies from the Group refers to public interest incorporated foundations, public interest incorporated associations, non-profit organizations, etc. which receive donations or subsidies of over 10 million yen per year within any of the past three years from the Group.
- (*7) A consultant, certified public accountant or other accounting professional, or lawyer or other legal professional who has received a substantial amount of monetary compensation or other consideration other than director / audit & supervisory board member compensation from the Group refers to those who received such consideration other than director / audit & supervisory board member compensation of over 10 million yen from the Group in any of the recent past three fiscal years or those who belong to an entity which receives such consideration from the Group in amount exceeding 2% of the said entity's consolidated sales or gross income.